Annual Cash & Cash Equivalents
$55.32 M
-$42.34 M-43.35%
December 31, 2022
Summary
- As of February 8, 2025, EGRX annual cash & cash equivalents is $55.32 million, with the most recent change of -$42.34 million (-43.35%) on December 31, 2022.
- During the last 3 years, EGRX annual cash & cash equivalents has fallen by -$54.45 million (-49.61%).
- EGRX annual cash & cash equivalents is now -51.75% below its all-time high of $114.66 million, reached on December 31, 2017.
Performance
EGRX Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$15.35 M
-$6.54 M-29.88%
June 30, 2023
Summary
- As of February 8, 2025, EGRX quarterly cash and cash equivalents is $15.35 million, with the most recent change of -$6.54 million (-29.88%) on June 30, 2023.
- Over the past year, EGRX quarterly cash and cash equivalents has dropped by -$21.21 million (-58.01%).
- EGRX quarterly cash and cash equivalents is now -92.40% below its all-time high of $202.02 million, reached on March 31, 2020.
Performance
EGRX Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
EGRX Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -43.4% | -58.0% |
| 3 y3 years | -49.6% | -85.8% |
| 5 y5 years | -51.8% | -84.7% |
EGRX Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -43.4% | at low | -84.3% | at low |
| 5 y | 5-year | -49.6% | at low | -92.4% | at low |
| alltime | all time | -51.8% | +991.8% | -92.4% | +53.9% |
Eagle Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2023 | - | $15.35 M(-29.9%) |
| Mar 2023 | - | $21.90 M(-60.4%) |
| Dec 2022 | $55.32 M(-43.4%) | $55.32 M(+259.6%) |
| Sep 2022 | - | $15.38 M(-57.9%) |
| Jun 2022 | - | $36.56 M(-47.4%) |
| Mar 2022 | - | $69.52 M(-28.8%) |
| Dec 2021 | $97.66 M(-5.3%) | $97.66 M(-2.1%) |
| Sep 2021 | - | $99.74 M(-8.3%) |
| Jun 2021 | - | $108.72 M(+3.3%) |
| Mar 2021 | - | $105.23 M(+2.0%) |
| Dec 2020 | $103.16 M(-6.0%) | $103.16 M(+15.0%) |
| Sep 2020 | - | $89.68 M(-17.1%) |
| Jun 2020 | - | $108.21 M(-46.4%) |
| Mar 2020 | - | $202.02 M(+84.0%) |
| Dec 2019 | $109.78 M(+39.3%) | $109.78 M(-6.3%) |
| Sep 2019 | - | $117.21 M(+8.4%) |
| Jun 2019 | - | $108.13 M(+5.9%) |
| Mar 2019 | - | $102.14 M(+29.6%) |
| Dec 2018 | $78.79 M | $78.79 M(-13.6%) |
| Sep 2018 | - | $91.23 M(-9.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $100.25 M(+4.8%) |
| Mar 2018 | - | $95.67 M(-16.6%) |
| Dec 2017 | $114.66 M(+117.1%) | $114.66 M(+17.5%) |
| Sep 2017 | - | $97.55 M(+76.1%) |
| Jun 2017 | - | $55.38 M(+99.9%) |
| Mar 2017 | - | $27.71 M(-47.5%) |
| Dec 2016 | $52.82 M(-33.2%) | $52.82 M(-10.9%) |
| Sep 2016 | - | $59.31 M(-21.5%) |
| Jun 2016 | - | $75.56 M(-3.5%) |
| Mar 2016 | - | $78.29 M(-1.0%) |
| Dec 2015 | $79.08 M(+248.0%) | $79.08 M(+9.9%) |
| Sep 2015 | - | $71.98 M(+425.9%) |
| Jun 2015 | - | $13.69 M(-86.3%) |
| Mar 2015 | - | $99.92 M(+186.6%) |
| Dec 2014 | - | $34.87 M(+53.5%) |
| Sep 2014 | $22.72 M(+117.3%) | $22.72 M(-54.4%) |
| Jun 2014 | - | $49.79 M(-9.3%) |
| Mar 2014 | - | $54.88 M(+450.2%) |
| Dec 2013 | - | $9.97 M(-4.6%) |
| Sep 2013 | $10.46 M(+106.4%) | $10.46 M |
| Sep 2012 | $5.07 M | - |
FAQ
- What is Eagle Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Eagle Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Eagle Pharmaceuticals?
- What is Eagle Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Eagle Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of EGRX is $55.32 M
What is the all time high annual cash & cash equivalents for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high annual cash & cash equivalents is $114.66 M
What is Eagle Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, EGRX annual cash & cash equivalents has changed by -$42.34 M (-43.35%)
What is Eagle Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of EGRX is $15.35 M
What is the all time high quarterly cash and cash equivalents for Eagle Pharmaceuticals?
Eagle Pharmaceuticals all-time high quarterly cash and cash equivalents is $202.02 M
What is Eagle Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, EGRX quarterly cash and cash equivalents has changed by -$21.21 M (-58.01%)